https://orcid.org/0000-0002-3788-8942, & ![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos. No fees are directly received personally. GB received small speaker’s fees from Bayer, Boston, Boehringer Ingelheim, Daiichi-Sankyo, Jansseen and Sanofi, outside the submitted work. All other authors have nothing to declare.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
![Novo Nordisk – Driving change to defeat serious chronic diseases.]({"type":"image" , "src" : "/sda/112384/TACD_NovoNordisk.jpg"})
![A bold vision to stop cardiovascular disease from being a leading cause of death.]({"type":"image" , "src" : "/sda/112402/JournalAd-amarin.jpg"})
